@article{32e87740c11c45f580154a9bc51375c8,
title = "Interleukin-4 as an emerging therapeutic target for IgG4-related disease",
keywords = "autoimmune diseases, autoimmunity, cytokines, inflammation, treatment",
author = "Mitsuhiro Akiyama and Yuko Kaneko and Tsutomu Takeuchi",
note = "Funding Information: Competing interests MA: reports no conflicts of interest relevant to this article. YK: has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi and UCB. TT: has received research grants or speaking fees from Astellas Pharma Inc, Bristol–Myers K.K., Chugai Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Takeda Pharmaceutical Co, Ltd, Teijin Pharma Ltd, AbbVie GK, Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., AbbVie GK, Nippon Kayaku Co Ltd, Janssen Pharmaceutical K.K., Taiho Pharmaceutical Co, Ltd, and Pfizer Japan Inc.",
year = "2022",
month = feb,
day = "1",
doi = "10.1136/annrheumdis-2020-216961",
language = "English",
volume = "81",
pages = "E28",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "2",
}